Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Link to 27 Jul Radio Interview:
http://www.mevio.com/episode/167473/FEN_090727
GLTA,
Murocman
I was having trouble downloading the investor presentation off their website so emailed IR for it. I got the presentation and had the following exchange:
John,
Mechanical completion is scheduled for year end, followed by commissioning, start up, ramp up and full rate operation by mid year.
We are all looking forward to getting the plant on line and getting on to our second plant.
Best regards.
Jeff
Thanks Jeff. Presentation works just fine and is impressive. It looks like Syntroleum is on the cusp of big things! When is the plant scheduled to be completed?
Thanks,
John Anderson
I have very little doubt there will be a second plant. As long as this one works as advertised, the demand will be there. Gas/oil prices will likely continue to trend higher and I think there is a strong chance the USAF/DOD will give this company a large contract to make them jet fuel. It is a great time to load the boat IMO. This company is in the process of leading the way in the creation of a new industry creating fuel from animal fat.
GLTA,
Murocman
Commercialization?
Does anyone have a sense for the company's plan and timeline to commercialize its technology? Organic manufacturing? Contract Manufacturing? Licensing? etc?
It seems to me that this is the next step. If the technology is as good as it looks at first glance, I would think they wouldn't have much of a problem getting a partner onboard to manufacture these things?
Thoughts?
GLTA,
Murocman
Still looking OK here IMO.
If we don't see the stock start to run up in anticipation of approval on Wed-Thur-Fri, I'll get concerned. This stock was around $1 in late April, so the action we're seeing may just be some 'nervous nellies' locking in their profits?
GLTA,
Murocman
I'll bite.
I'm looking for $2.50-3.50 pre-approval. If we can get above $3 on good volume, that would be very bullish, as that is the prior most recent high for the stock.
Assuming we get above $3, and we do get approval at the end of the week, I'd look for $5-6 on approval. If the company follows up with a partnership deal in the short-term, $10 is not out of the question IMO.
GLTA,
Murocman
DJ Newswire Stories (there were two) :
2:37 (Dow Jones) Canadian biotech Labopharm (DDSS) has seen its stock jump 30% already this month, despite underwhelming initial prescription data for its Ryzolt painkiller. RBC Capital Markets says the market's attention is now focused on US approval of its second drug, anti-depressant trazodone, which could come by July 18. "Given the poor performance to date of Ryzolt, the company's dependence on a favorable decision by the FDA for trazodone...has increased in importance," RBC says. DDSS up 8.1% at $2.66. (AMG)
By Andy Georgiades
Of DOW JONES NEWSWIRES
TORONTO (DOW JONES)--Labopharm Inc. (DDSS) has made a great deal of progress in partnership talks for its Trazodone drug, but it sees no reason at this point to sign a deal until a U.S. regulatory decision is made, its top executive said.
In an interview with Dow Jones, James Howard-Tripp said that, with only two weeks to go until the U.S. Food and Drug Administration makes a decision, there would be "no logic" in finalizing a marketing pact now.
The FDA is expected to make a decision by July 18.
"With most groups, once you get to within a couple of weeks of the (FDA's deadline) date, (they're) probably a little reluctant to sign," he said, adding that Labopharm would also prefer to wait.
Assuming a positive decision, Labopharm would want to complete the partnership "fairly rapidly" after approval, with the aim of launching the drug "very early" in 2010, he said.
Trazodone has many generics available, but Labopharm's version is taken only once daily and can help patients sleep better.
Labopharm's stock has been on a tear, up 28% in July alone, mainly on anticipation of a regulatory decision on Trazodone and/or a partnership.
Canaccord Adams analyst Neil Maruoka said in a note Monday that he believes Trazodone has a "better-than-average" approval chance.
"A positive decision would likely result in a pop in the stock and point to a potential partnership for the drug in the near-term," he wrote. He rates the stock a buy.
On Nasdaq Monday, Labopharm is up 7 cents to $2.53 on 980,000 shares.
GLTA,
Murocman
Dilution would definitely throw cold water on this stock. I haven't been able to find out if there are any convertibles hanging out there.
The fact that this is a Canadian company makes that a bit tougher. Will keep digging today and post if I find anything.
GLTU,
Murocman
Price-volume action has really put a new twist on this stock. Moving up like it did on 7-8x average daily volume with no news, and on a down, pre-holiday market. As long as there aren't any dilution triggers looming, this is very bullish for this stock. I wouldn't be surpised to see this move past $3 next week, and then probably pull back as we get closer to the PDUFA date.
GLTA,
Murocman
That may be true, but I wouldn't hang with this one very long. There isn't anything on their website except a description of what the plan to do for a business model, and no information on Pinksheets.com. While I'll admit a contract with Rastelli possibly adds some validity, I can't find any third party confirmation.
Bottom line...get in quick and take profits earlier rather than later.
GLTA,
Murocman
In what timeframe? That would put the market cap over $100M with current O/S of approx 589 million. I really can't see that happening. This is a non-reporting pinksheet company. Play the momentum if it comes and at least take your original investment out and let the rest ride. To quote a very wise trader on another board, play em', don't marry em'!
GLTA,
Murocman
SFIO probably going to run short term per OTCBB alerts Board.
GLTA, Murocman
Don't forget that Advaxis is in licensing talks for its flagship vaccine. They delayed their annual meeting per the PR in late April due to the discussions. Any positive announcement regarding licensing with a major partner will make today's selloff look like a tremendous buying opportunity IMO. The question is when?
GLTA,
Murocman
Advaxis (ADXS.OB) getting attention.
This stock traded almost $1.2M in volume on almost 7.8M shares on Friday. Both are all time highs for the stock going back to 2005. It went up on no news. Somone (and not retail investors with that kind of money) was accumulating. Ophan Drug Designation by the FDA and a licensing deal are pending. Get onboard and enjoy the ride. Take profits on the way up before the money flow dries up. Make money. Don't fall in love with the stock.
GLTA,
Murocman
Follow the Money Flow
This stock traded almost $1.2M in volume on almost 7.8M shares on Friday. Both are all time highs for the stock going back to 2005. It went up on no news. Somone (and not retail investors with that kind of money) was accumulating. Ophan Drug Designation by the FDA and a licensing deal are pending. Get onboard and enjoy the ride. Take profits on the way up before the money flow dries up. Make money. Don't fall in love with the stock.
GLTA,
Murocman
ADXS up to $0.10 from $0.03 since alert
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37142684
Up 100% on very heavy volume today. FDA Orphan drug decision due by 9 May and pending/possible licensing agreement. 52 week high is $0.14.
GLTA,
Murocman
Isn't the re-zoning just the first preliminary step? What about the whole process of getting the permits from the NRC?
The bit of reading I have done on this subject in the past indicated that was the real reason the we haven't built any new plants.
The permit process is very onerous, expensive, time consuming and slanted towards the environmentalist crowd that are simply anti-progress and use the fact that this is Nuclear power and somehow equate it to Three-Mile Island and/or Chernobyl and there's going to be tons of waste (never mind that ALL of the high level waste produced to date would fit easily in a gymnasium) and that resonates so the proposals have been killed.
Not trying to be a wet blanket, but not seeing this being re-zoned as the panacea that will make this even a $0.15 stock let alone $1. It may get there, but I think it's way too early.
JMO,
Murocman
Don't forget about earnings...hopefully after the close tomorrow. Could be a nice catalyst to sustain the run if the losses are not too bad and the outlook is positive.
GLTA,
Murocman
Meeting of Creditors on 17 June:
http://www.kccllc.net/chemtura
Didn't see this previously posted.
Murocman
ADSX had huge volume today ans was up 20%. I went back and looked at the share volume dating all the way back to 2005 and we beat the highest amount ever by a factor of 2.
Management is either using the news release from Friday as an opportunity to dilute, OR there was simply a lot of turnover/OH resistance given this stock is at it's lows and people were using the volume as a chance to get out.
It will be telling to watch the price and volume action over the next few days to see which of the above is the case.
It looks like good things may be in the offing for this company. I took a starter position today. We'll see whether it was a wise move or not.
GLTA,
Murocman
I went back and looked at the share volume dating all the way back to 2005 and we beat the highest amount ever by a factor of 2.
Management is either using the news release from Friday as an opportunity to dilute, OR there was simply a lot of turnover/OH resistance given this stock is at it's lows and people were using the volume as a chance to get out.
It will be telling to watch the price and volume action over the next few days to see which of the above is the case.
It looks like good things may be in the offing for this company. I took a starter position today. We'll see whether it was a wise move or not.
GLTA,
Murocman
ADXS on potential licensing news:
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc (ADXS). is in drug licensing discussions for its flagship vaccine construct, ADXS11-001(formerly named Lovaxin-C), in non-US markets.
Due to the potential materiality of the aforementioned event, Advaxis (ADXS) ' annual general meeting, which was scheduled for Wednesday, April 22, 2009 will be postponed and rescheduled after the licensing contract is completed.
ADXS11-001 is a therapeutic vaccine, like Dendreonâs Provenge, that treats active cancer, but much lower cost because it is not formulated for a specific patient. Unlike currently marketed prophylactic vaccines, ADXS 11-001 treats women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection; the most prevalent sexually transmitted disease in the US today. Advaxis (ADXS) has already filed an IND for a Phase II trial in HPV caused cervical intraepithelial neoplasia (CIN), which is pre-cancerous.
About the ADXS11-001 Immunotherapy
Advaxisâ technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Pre-clinically, bioengineered attenuated Listeria that secrete Advaxisâ proprietary fusion protein have the ability to generate a robust immune response, break immune tolerance to cancer and produce an unusually strong and effective multi-level therapeutic immune response to existing cancer and other diseases.
Advaxisâ Listeria-based technology is based on over a decade worth of work by Dr. Yvonne Paterson in her laboratory at the University of Pennsylvania. The Companyâs proprietary antigen fusion protein technology stimulates innate immunity i.e., both arms of the adaptive cellular immune system, suppresses regulatory T-cells that inhibit many vaccines in the function of activated tumor-killing cells in addition to other anti-tumor effects.
For further information on ADXS11-001, please visit: www.advaxis.com/lc.htm.
About Advaxis, Inc. (ADXS)
Based in North Brunswick, New Jersey, Advaxis (ADXS) is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxisâ scientific advisory board. Advaxis (ADXS) is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
For further information on the Company, please visit: www.advaxis.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Companyâs current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Source: Advaxis, Inc (ADXS)
Anybody have any thoughts on the fact that Chemtura had made statements about an asset sale by the end of March, but still nothing? I'm thinking maybe either they couldn't get the price they were looking for, OR business has improved such that they may be having second thoughts.
Either way, I'd expect we get a little more clarity when earnings come out, if not before.
GLTA,
Murocman
Looks like promisinng news out after the bell on Friday:
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc (ADXS). is in drug licensing discussions for its flagship vaccine construct, ADXS11-001(formerly named Lovaxin-C), in non-US markets.
Due to the potential materiality of the aforementioned event, Advaxis (ADXS) ' annual general meeting, which was scheduled for Wednesday, April 22, 2009 will be postponed and rescheduled after the licensing contract is completed.
ADXS11-001 is a therapeutic vaccine, like Dendreonâs Provenge, that treats active cancer, but much lower cost because it is not formulated for a specific patient. Unlike currently marketed prophylactic vaccines, ADXS 11-001 treats women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection; the most prevalent sexually transmitted disease in the US today. Advaxis (ADXS) has already filed an IND for a Phase II trial in HPV caused cervical intraepithelial neoplasia (CIN), which is pre-cancerous.
About the ADXS11-001 Immunotherapy
Advaxisâ technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Pre-clinically, bioengineered attenuated Listeria that secrete Advaxisâ proprietary fusion protein have the ability to generate a robust immune response, break immune tolerance to cancer and produce an unusually strong and effective multi-level therapeutic immune response to existing cancer and other diseases.
Advaxisâ Listeria-based technology is based on over a decade worth of work by Dr. Yvonne Paterson in her laboratory at the University of Pennsylvania. The Companyâs proprietary antigen fusion protein technology stimulates innate immunity i.e., both arms of the adaptive cellular immune system, suppresses regulatory T-cells that inhibit many vaccines in the function of activated tumor-killing cells in addition to other anti-tumor effects.
For further information on ADXS11-001, please visit: www.advaxis.com/lc.htm.
About Advaxis, Inc. (ADXS)
Based in North Brunswick, New Jersey, Advaxis (ADXS) is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxisâ scientific advisory board. Advaxis (ADXS) is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
For further information on the Company, please visit: www.advaxis.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Companyâs current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Source: Advaxis, Inc (ADXS)
Did you bother to open it? It's their de-listing from the NYSE.
GLTU,
Murocman
How likely is it that this company will sell off assets voluntarily (and soon) such that they might be able to expedite emergence from bankruptcy?
Given that the Chinese backed out at $1B, I'm thinking the onlyother folks with deep enough pockets to outbid them are the Saudi's, UAE or Qatari's.
Looking for any insight, as I'm not that familiar with what might be considered "extraneous" businesses worthy of shedding for cash.
Thanks,
Murocman
Nice recovery and good volume today. Hopefully a harbinger of the price appreciation to follow. I think this will need some contract/installation news to get the sustained volume and and price appreciation going.
Hopefully that will occur within next month?
GLTA,
Murocman
Stock up 32% today on great news and no interest? Looks like good things to come with this company.
Murocman
Anybody have any thoughts on the odds that this will make it to $0.02 sometime this week?
GLTA,
Murocman
I only entered the trade Friday at 0.0089. If I remember my three minute chart, it ran from .005 at the open up to .009, pulled back to .007, ran up .011, pulled back to .009, then ran to .014. This kind of continued all day. It was running pretty hard towards 0.02 at the end of the day. It hit the .018-.019 area about five minutes before the close and sellers took it down to the .015-.016 area.
If there isn't any news before the open, I'd expect it to pull back a bit.
Murocman
$.0.04 will be the key resistance level if this does continue to run, as that is the old high. If it does continue to push higher on Monday and approach that level, pay particular attention to how it acts. You'd be looking for strong buying volume on any pullbacks from $0.04 as a sign folks are looking to support this to higher levels IMO.
GLTA,
Murocman
I didn't say they wouldn't use embryonic stem cells. Only that it does not appear that they are, based on current and past agreements.
As I said, I also don't think the prospects of "opening" the embryonic stem cell market supports a 255% gain on almost 10x average volume. There is something specific (merger, partnership, etc.) that is brewing IMO, that has sparked the sudden interest.
Here's to a profitable trade for all of us.
Murocman
This is a different issue. As I look through the MultiCell website, their focus on adult stemcells from the liver. Adult stemcells are already in use and have shown excellent promise in multiple therapies.
Embryonic cells get more press but adult stem cells have more near-term potential.
Bottomline, I don't think the story you reference is the reason for this move. The volume is too high and the move too great. There is something else going on that the public isn't privy to yet, but obviously somebody thinks it's good news.
Murocman
I don't ever blame anyone for taking profits. You have to stay true to your strategy/style. This is about making money first and foremost.
In this case, I too like the higher plateau, and am going to hang around until the 'rest of the story becomes known', as I'm betting that will drive the price back towards the .04-.05 range.
JMO,
Murocman
I'm definitely liking the price-volume action! Just touched .014. Might see .02 today?
Murocman
Thanks, I did. I still find the price-volume action very curious given the relative quietness of the company and it's activities.
Murocman
MCET ($0.012), up 180% & on the move again
Murocman
Anybody have any thoughts on reason for the big move and volume?
It looks like this company has been (and hopefully still is) associated with several heavy-hitter pharmaceutical companies such as Merck, Bristol-Meyers, etc in the past. However it doesn't look like much has gone on in the last year+.
Given that, I don't think you'd see this kind of move and volume just over optimisim on stem cells, especially given that this company focuses on adult stem cells from the liver, which hasn't been controversial.
My thought is that there is some yet-to-be announced development that is prompting all of the action.
Anybody have anymore insight?
Murocman
MCET (.0088) Up over 100% on huge volume and no news.
Murocman
Megola Signs $50M Agreement With Vulcan Technologies for 10 Year Railroad Contract
Tuesday January 20, 4:00 pm ET
Agreement Provides for Megola to Receive $750,000 Working Capital Advance on Future Royalty Payments
POINT EDWARD, ON--(MARKET WIRE)--Jan 20, 2009 -- Megola Inc. (Other OTC:MGOA.PK - News) announced the signing of a Distribution and Sale Agency and Royalty Agreement with Vulcan Technologies, LLC, for the Hartindo line of Anti-Fire Products.
Joel Gardner, President and CEO of Megola Inc., stated, "Megola continues to move forward with its goal of bringing the Hartindo Line of Anti-Fire Products to the North American marketplace. With the successes of the advanced testing to date, we continue to demonstrate that Hartindo products are the next generation of fire inhibiting and extinguishing products from both an industry efficacy and environmental impact point of view. Attracting a company such as Vulcan shows how far reaching and lucrative the product applications can be."
Highlights of the Agreement include, but are not limited to, the following:
-- Vulcan is granted exclusive distribution/sales representative rights
for the Hartindo Product Line in the countries of Canada and Mexico
to the railroad industry (the "Railroad Industry") for a ten (10)
year term.
-- Vulcan is granted co-exclusive distribution/sales representative rights
for the Hartindo Product Line in the United States of America
(the "U.S."), to the railroad industry (the "Railroad Industry") for a
ten (10) year term.
-- In consideration of its appointments set forth in the Agreement, Vulcan
agrees to pay Megola the sum of Seven Hundred Fifty Thousand
($750,000.00) USD, as follows:
(i) a partial payment of $400,000 to Megola due five (5) business
days after the execution and delivery of this Agreement by all
parties, and;
(ii) a payment of $350,000 ninety (90) days following the date of this
Agreement.
-- Vulcan shall pay to Megola a commission payment equal to twenty-five
(25%) percent of Vulcan's profit on Hartindo Products.
-- Vulcan hereby commits to generate aggregate gross sales of the Hartindo
Products in the Railroad Industry of no less than $3 Million USD on or
before the second anniversary of this Agreement, and, thereafter,
agrees to increase such aggregate gross sales by fifteen (15%) percent
for each year thereafter, commencing with the third year of the term.
ADVERTISEMENT
About Vulcan Technologies, LLC:
Vulcan Technologies, LLC (Vulcan), incorporated in the State of New Jersey, was founded with the sole purpose of distributing a complete line of proprietary and environmentally-friendly "green" products. Vulcan's management has extensive investment banking experience and contacts in many different sectors throughout the United States and Canada, including the real estate, garment, and hospital industries, and is actively conducting business with major North American railroads. In addition to management, several Vulcan advisors have years of experience securing military, municipal and security contracts throughout North America, which will assist in establishing a substantial market presence for the Hartindo product line.
For more info on Megola Inc., please visit www.megola.com
ACCC Transmission Lines
This will be the real growth driver for this company in the next year IMO, and the turbine business will be icing on the cake if if China and the US do indeed follow through with a massive buildup in windpower.
As long as this company can stay financed, liquid and not create too much share dilution, it and the shareholders ought to do very well.
GLTA,
Murocman